Last $1.62 USD
Change Today +0.0647 / 4.17%
Volume 28.7K
CRMD On Other Exchanges
Symbol
Exchange
NYSE Amex
As of 12:00 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

cormedix inc (CRMD) Snapshot

Open
$1.57
Previous Close
$1.55
Day High
$1.63
Day Low
$1.57
52 Week High
03/3/14 - $3.20
52 Week Low
12/26/13 - $1.00
Market Cap
36.2M
Average Volume 10 Days
27.0K
EPS TTM
$-0.91
Shares Outstanding
22.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CORMEDIX INC (CRMD)

Related News

No related news articles were found.

cormedix inc (CRMD) Related Businessweek News

No Related Businessweek News Found

cormedix inc (CRMD) Details

CorMedix Inc., a development-stage pharmaceutical and medical device company, intends to in-license, develop, and commercialize therapeutic products for the treatment of cardiorenal and infectious diseases. The company’s product candidates include CRMD003 (Neutrolin) and CRMD004, an antimicrobial/antifungal and anticoagulant combination in liquid and gel formulations used for the prevention of catheter-related blood stream infections and maintenance of catheter patency in hemodialysis patients. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix Inc. in January 2007. CorMedix Inc. was founded in 2006 and is based in Bridgewater, New Jersey.

2 Employees
Last Reported Date: 03/31/14
Founded in 2006

cormedix inc (CRMD) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $223.5K
Vice Chairman, Chief Scientific Officer and C...
Total Annual Compensation: $120.0K
Compensation as of Fiscal Year 2013.

cormedix inc (CRMD) Key Developments

CorMedix Inc. Finalizes First Middle East Neutrolin Sales/Distribution Agreement in the Kingdom of Saudi Arabia

CorMedix, Inc. announced the first signed Middle East sales/distribution agreement for lead product Neutrolin with distributor Arabian Trade House in the Kingdom of Saudi Arabia. CorMedix's Neutrolin is a novel formulation of taurolidine, citrate and heparin with 1,000 u/ml that provides a combination preventative solution, decreases the triple threat of infection, thrombosis, and biofilm to keep catheter's operating safely and efficiently by optimizing catheter blood flow while minimizing infections and biofilm formation.

CorMedix, Inc. Receives Label Expansion from the Hessian District President in Germany for Neutrolin

CorMedix Inc. announced the approval of a label expansion from the Hessian District President in Germany for its product Neutrolin, a catheter lock solution. Neutrolin use in the prevention of catheter-related bloodstream infections (CRBI) and maintenance of catheter patency in hemodialysis patients using a tunneled, cuffed central venous catheter for vascular access. This approval expands the label to include use in oncology patients receiving chemotherapy, IV hydration and IV medications via central venous catheters. The expansion also adds patients receiving medication and IV fluids via central venous catheters in intensive or critical care units (cardiac care unit, surgical care unit, neonatal critical care unit, and urgent care centers). An indication for use in total parenteral, or IV, nutrition was also approved.

CorMedix Inc. Files Request with FDA for QIDP Designation for Neutrolin(R)

CorMedix, Inc. has filed a request with the U.S. Food and Drug Administration (FDA) for designation of its lead product candidate, Neutrolin(R) Catheter Lock Solution, as a qualified infectious disease product (QIDP) pursuant to the Generating Antibiotic Incentives Now (GAIN) title of the Food and Drug Administration Safety and Innovation Act (FDASIA). Neutrolin contains taurolidine, which has been shown to be a potent anti-infective agent that is active against gram positive and gram negative bacteria, and also contains heparin to ensure patency of the catheter. CorMedix is requesting designation of Neutrolin as a QIDP to secure incentives, such as the 5 year extension of marketing exclusivity, for pursuing marketing approval in the U.S. CorMedix intends to conduct clinical trials with Neutrolin(R) Catheter Lock Solution in hemodialysis patients and oncology patients, where catheter-related blood stream infections can be life-threatening and infection of catheters with antibiotic resistant bacteria can result in catheter removal.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CRMD:US $1.62 USD +0.0647

CRMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CRMD.
View Industry Companies
 

Industry Analysis

CRMD

Industry Average

Valuation CRMD Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CORMEDIX INC, please visit www.cormedix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.